Summary of the Conference Call for Xinwei Medical Company Overview - **Company**: Xinwei Medical - **Industry**: Medical Devices, specifically in neurointerventional products Key Points Revenue and Growth Targets - **Revenue Growth Target**: Company aims for a continuous revenue growth of 35% over the next three years, driven by advancements in ischemia, hemorrhage, and access product segments, along with international market expansion [2][3] - **Profit Margin Goals**: Targeting a net profit margin of 20% with a long-term gross margin stabilizing between 68% and 70% [2][5] Product and Market Strategy - **Product Structure Optimization**: By 2025, the revenue from therapeutic products is expected to dominate at 60%, shifting from access products, which enhances gross margins from 65% to 70.9% [2][5] - **International Market Expansion**: Anticipates overseas sales exceeding 100 million RMB by 2028, with significant focus on India, Belarus, and Latin America [2][3] Competitive Landscape and Pricing Strategy - **Collective Procurement Impact**: The normalization of collective procurement has increased the domestic product localization rate from 10% to 40%, with significant price reductions in surgical consumables [4] - **Future Pricing Trends**: Prices are expected to stabilize with gradual reductions rather than drastic fluctuations, benefiting established companies with strong quality and service capabilities [4] Financial Performance and Projections - **Gross Margin Improvement**: The gross margin is projected to rise due to a shift towards higher-margin therapeutic products and cost optimization strategies [5] - **Sales Growth Drivers**: Key products driving growth include suction catheters and drug-eluting stents, with expectations for high growth in the ischemia segment [5][6] Financing and Investment Plans - **A-Share Financing**: Plans to raise 800 million RMB for capacity expansion and R&D in niche areas and brain-machine interface development [2][6] - **Production Capacity Expansion**: Expansion of production facilities in Shanghai and Nanjing is underway to support future growth [6] Brain-Machine Interface Development - **Product Development Timeline**: The company is working on an invasive brain-machine interface, with expected certification by 2028, benefiting from supportive government policies [2][7][8] - **Clinical Trial Plans**: Clinical trials are focused on motor impairment patients, with a clear direction for regulatory approval and market entry [9][10] Market Positioning and Future Strategy - **Long-term Market Leadership Goal**: Aiming to become the leading player in the domestic neurointerventional market by focusing on product quality, brand building, and strategic partnerships with key opinion leaders [11][12] - **Shareholder Returns**: Plans to enhance shareholder returns through stock buybacks and dividends post-A-share listing [11][12] Additional Insights - **Sales Model**: The company employs a mix of distribution and self-built teams in overseas markets, with a focus on brand building and customer relationships [10][11] - **Market Dynamics**: The neurointerventional market is characterized by a concentration of demand in top-tier hospitals, prompting a strategic shift in focus from grassroots to leading hospitals [12] This summary encapsulates the essential insights from the conference call, highlighting the company's strategic direction, financial goals, and market positioning within the neurointerventional industry.

Summary of the Conference Call for Xinwei Medical Company Overview - **Company**: Xinwei Medical - **Industry**: Neurointerventional Devices Key Points and Arguments Strategic Transformation and Profitability - **Shift from Distribution to Treatment**: The company has transitioned from a distribution-focused model to a treatment-oriented approach, achieving a net profit exceeding 50 million yuan in H1 2025, marking a turnaround from losses to profitability. Revenue growth is expected to exceed 40% in 2025, with gross margins projected to exceed 70% [2][4][6]. Market Potential and Domestic Replacement - **Significant Domestic Market Opportunity**: In 2023, foreign brands held 75% of the Chinese neurointerventional market. The company has obtained 32 product registrations and has successfully bid for multiple products in group purchasing, accelerating penetration into 2,500 hospitals [2][4]. Breakthrough Products - **Innovative Drug-Eluting Stent**: The self-expanding drug-eluting stent has completed head-to-head clinical trials with positive results and is expected to receive approval by Q4 2026, potentially becoming the first drug-eluting stent for intracranial artery stenosis in China [2][4][5][9]. Brain-Machine Interface (BMI) Development - **First-Mover Advantage**: The company is the first in China to develop an interventional brain-machine interface, comparable to Synchron, having completed animal trials and planning human clinical trials in 2026, with expected approval in 2027-2028 [2][4][12]. Financial Performance and Future Projections - **Strong Revenue Growth**: Since its IPO in 2021, the company has achieved continuous revenue growth, with a minimum growth rate of 20%. H1 2025 revenue grew approximately 44%, with full-year growth expected to exceed 40%. The net profit forecast for 2025-2027 is 71 million, 106 million, and 166 million yuan, representing year-on-year growth rates of 623%, 49%, and 56% respectively [2][6][7]. Product Line and Market Position - **Comprehensive Product Matrix**: The company has a diverse product line with 32 registered products, aiming to exceed 50. It is positioned as a second or third-tier player in the industry, focusing on high-value treatment products rather than solely on distribution [2][4][8]. Competitive Landscape - **Market Competition**: Despite foreign brands dominating the market, there is significant room for domestic replacements. The company has demonstrated strong competitiveness in group purchasing, winning bids for several products [2][8]. Risks and Challenges - **Key Risks**: The company faces risks related to ongoing price reductions in neurointerventional products due to national group purchasing and uncertainties regarding the progress of human clinical trials for the brain-machine interface [3][13]. Additional Important Information - **Clinical Data for Drug-Eluting Stent**: The stent has shown a re-stenosis rate below 5% and low mortality rates in clinical trials, with expected registration approval in Q4 2026 [9]. - **BMI Technology Comparison**: The company’s interventional BMI technology is positioned between invasive and non-invasive methods, offering a balance of safety and signal quality [10][12]. - **International Benchmarking**: Synchron's Stentrode has been successfully implanted in over 10 patients globally, showcasing the potential of interventional BMIs [11]. This summary encapsulates the critical insights from the conference call, highlighting the company's strategic direction, market opportunities, financial outlook, and associated risks.

Financial Performance - The company reported a revenue of RMB 408.3 million for the fiscal year ending December 31, 2025, representing a year-on-year increase of 46.9%[3]. - Gross profit reached RMB 289.5 million, with a gross margin of 70.9%, up from 65.4% in the previous year, reflecting a 5.5 percentage point improvement[3][6]. - The company achieved a significant turnaround with a net profit of RMB 83.3 million, compared to a net loss of RMB 13.6 million in the previous year, marking a 711.8% improvement[4]. - Total revenue for 2025 reached RMB 408,286 thousand, a significant increase of 47.0% compared to RMB 277,899 thousand in 2024[21]. - Revenue from medical device sales was RMB 407,766 thousand in 2025, up from RMB 276,931 thousand in 2024, reflecting a growth of 47.1%[21]. - The net profit attributable to shareholders was RMB 83.3 million, a significant turnaround from a net loss of approximately RMB 13.6 million in the previous year[39]. - Revenue increased by 46.9% from RMB 277.9 million for the year ending December 31, 2024, to RMB 408.3 million for the year ending December 31, 2025, driven by increased market share in ischemic stroke treatment devices and sales of hemorrhagic stroke treatment devices[65]. Business Segments - The ischemic stroke business revenue grew by 31.8%, driven by the recognition of the intracranial thrombectomy catheter and increased sales of mature products[4]. - The hemorrhagic stroke business saw a remarkable revenue increase of 223.2%, supported by the comprehensive treatment solutions and the introduction of new products[4]. - The company's vascular occluder product was used in over 1,800 hospitals, achieving over RMB 100 million in revenue for the year[5]. Research and Development - Research and development expenses were RMB 40.8 million, primarily focused on innovative products in neurointerventional medical devices[7]. - The company is advancing the development of a second-generation vascular occluder to further expand market share[5]. - The company is advancing the development of a brain-machine interface, expected to initiate the first human clinical trial in 2026[42]. - The innovative brain-computer interface (BCI) product is expected to begin its first human clinical trial in 2026, utilizing a minimally invasive approach to capture EEG signals[57]. - R&D costs decreased from RMB 58.9 million to RMB 40.8 million, primarily due to reduced third-party contracting costs and lower employee costs[69]. Market Expansion - Overseas market revenue increased by 101.3%, attributed to rapid product registration and promotion efforts, with multiple certifications obtained in various countries[8]. - The company has 35 medical device products approved by NMPA, three products approved by FDA, and one product with CE mark as of the announcement date[44]. - The company is evaluating opportunities to expand the indications and overseas marketing for the Captor stent, potentially applying for registration in the U.S.[48]. Financial Position - Total assets net of current liabilities increased to RMB 1,197,601 thousand in 2025 from RMB 1,123,824 thousand in 2024, marking a growth of 6.6%[11]. - The company's net assets rose to RMB 1,132,351 thousand in 2025, up from RMB 1,062,248 thousand in 2024, indicating a growth of 6.6%[11]. - Non-current liabilities totaled RMB 65,250 thousand in 2025, slightly up from RMB 61,576 thousand in 2024, reflecting an increase of 6.0%[11]. - Trade receivables decreased to RMB 64,335,000 in 2025 from RMB 97,381,000 in 2024, with an expected credit loss rate of 2.57%[33][35]. - The company has a net trade receivable value of RMB 62,682,000 as of December 31, 2025, after accounting for impairment losses[34]. Expenses and Income - Other income totaled RMB 50,401 thousand in 2025, compared to RMB 23,099 thousand in 2024, showing a substantial increase of 118.9%[23]. - The company reported a decrease in bank interest income to RMB 6,243 thousand in 2025 from RMB 8,766 thousand in 2024, a decline of 29.0%[23]. - Inventory impairment increased to RMB 17,356 thousand in 2025 from RMB 8,056 thousand in 2024, representing a rise of 115.2%[25]. - The company reported a tax expense of RMB 3,073,000 for 2025, compared to RMB 1,630,000 for 2024, reflecting an increase in tax obligations due to improved financial performance[28]. - Other income and gains increased from RMB 23.1 million to RMB 50.4 million, attributed to higher government subsidies and fair value gains on financial assets[68]. Corporate Governance and Compliance - The audit committee, consisting of three members, has reviewed the group's accounting principles and internal controls, ensuring compliance with relevant accounting standards and regulations[98]. - The external auditor, Ernst & Young, confirmed that the financial data in the announcement aligns with the audited consolidated financial statements for the reporting period[99]. - The company has adopted a standard code of conduct for directors and senior management regarding the trading of company securities during the blackout period, which lasts for 30 days prior to the announcement of interim results[96]. - During the blackout period, an executive director's spouse sold a total of 99,650 H-shares at prices ranging from HKD 52.0 to HKD 65.2 per share, violating the standard code of conduct[96]. Shareholder Information - The company did not declare or pay any dividends in 2025, consistent with 2024[30]. - The board has proposed to issue 1,000,000 domestic shares at a subscription price of HKD 45.00 per share, pending shareholder approval[85]. - The company repurchased a total of 632,850 H-shares for approximately HKD 39.4 million during the fiscal year ending December 31, 2025[90]. - The company has maintained the required public float as per listing rules as of the announcement date[88]. - The annual general meeting is scheduled for May 28, 2026, with a cutoff date for share transfer registration on May 22, 2026[93].

董事會召開日期 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 上海心瑋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 宣佈，本公司將於2026年3月26日（星期四）舉行董事會會議，藉以（其中包括） 審議及批准本公司及其附屬公司截至2025年12月31日止年度之全年業績及其發 佈，以及考慮建議派付末期股息（如有）。 承董事會命 上海心瑋醫療科技股份有限公司 董事長 王國輝 上海，2026年3月16日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry in China [6] Core Viewpoints - The report emphasizes that semi-invasive brain-machine interfaces (BMIs) demonstrate significant safety advantages over invasive methods, making them more suitable for consumer applications [9][10] - The potential for semi-invasive BMIs to address safety concerns during implantation, long-term use, and removal is highlighted, suggesting a greater development potential [9][10] - The report identifies that the market for BMIs is expected to grow significantly, particularly in the treatment of neurological diseases, which will pave the way for future consumer-level applications [19][21] Summary by Sections 1. Semi-Invasive Surgery: Smaller Incisions and Shallow Implantation - Semi-invasive techniques are less invasive, reducing surgical risks compared to invasive methods [9][10] - The report notes that semi-invasive BMIs can achieve shallower implantation depths, minimizing damage to brain tissue [9][10] - The potential for algorithm advancements to further enhance implantation techniques is discussed [49] 2. Long-Term Safety and Higher Channel Limits - Semi-invasive BMIs do not form scar tissue, maintaining neuron integrity, which is crucial for long-term stability [51][57] - The report indicates that semi-invasive designs can avoid electrode displacement, which is a significant risk in invasive methods [61][67] - The ability of semi-invasive BMIs to manage thermal limits effectively is emphasized, allowing for higher channel counts without compromising safety [69][73] 3. Safer Removal and Greater Consumer Potential - The report highlights that removing semi-invasive electrodes poses less risk of damaging blood vessels compared to invasive electrodes [11][14] - The increasing frequency of hardware upgrades in BMIs necessitates safer removal methods, which semi-invasive designs can provide [11][14] - The report suggests that as the market for BMIs expands, semi-invasive methods will better meet consumer demands for easy replacement and upgrades [11][14] 4. Investment Recommendations and Targets - The report recommends focusing on semi-invasive BMI solutions with clear clinical progress and government support [14] - It suggests exploring companies within the semi-invasive BMI supply chain that show potential breakthroughs in the medical field and can extend into consumer markets [14]

Group 1: Pharmaceutical and Biotechnology Sector - Four Seasons Pharmaceutical (00460) saw a stock increase of 3.7% after receiving approval from the NMPA for its innovative drug, Pyrocilin Tablets, for treating HR+/HER2- advanced breast cancer [1] - Hengrui Medicine (01276) rose over 5% following the approval of a clinical trial for HRS-1780 Tablets aimed at treating primary hyperaldosteronism [3] - Mirxes-B (02629) experienced a stock surge of 10.86% after announcing a strategic partnership with Apollo Health to develop advanced cancer early detection solutions in India [3] - Cornerstone Pharmaceuticals-B (02616) increased by 12.37% after receiving FDA approval for its IND application for CS2009, a tri-specific antibody for advanced solid tumors [4] - Deciphera Pharmaceuticals-B (06996) rose 16.77% after signing an agreement with U.S. Biotech for the global development and commercialization of ATG-201, a dual-specific T-cell engager [5] Group 2: Automotive Sector - Automotive stocks showed a collective rebound, with XPeng Motors-W (09868) up 3.14% and NIO-SW (09866) up 3.43%, driven by news of BYD's upcoming launch of its second-generation blade battery and fast-charging technology [2] Group 3: Technology and Communication Sector - Optical communication stocks rallied, with Cambridge Technology (06166) up 8.7% after NVIDIA announced a $40 billion investment in optical technology through partnerships with Lumentum and Coherent [1] - Brain-computer interface stocks surged, with Nanjing Panda Electronics (00553) increasing by 24.64% following government reports emphasizing the development of future industries, including brain-computer interfaces [2] Group 4: Cryptocurrency Sector - Cryptocurrency-related stocks rebounded, with Okex Cloud Chain (01499) rising 15.89% as Bitcoin surpassed $72,000, driven by short-covering amid geopolitical concerns [5][6]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 2. 股份分類 | ...

Company Performance Goals - The company announced a revenue target of no less than 540 million yuan and a profit target of no less than 100 million yuan for the year 2026, demonstrating confidence in performance growth [1] Product Development Progress - The self-expanding intracranial drug-eluting stent's registration application was accepted by the National Medical Products Administration in January 2026, with certification expected by the end of 2026, potentially becoming the world's first product of its kind [2] - Products such as the spring coil are expected to receive overseas market certification in the first quarter of 2026, accelerating international expansion [2] Business Development Status - The interventional brain-computer interface project has completed technical validation, with the first human clinical trial expected to start in 2026 and a registration application planned for 2028, laying the foundation for innovation breakthroughs in the field of neuromodulation [3] Strategic Advancement - The company plans to apply for listing on the Sci-Tech Innovation Board in 2026 based on 2025 financial data and is currently in the listing guidance phase, which, if successful, will enhance the liquidity of its capital platform [4]

Group 1 - The core viewpoint of the article highlights that Xinyi Medical achieved a turnaround in 2025, reporting a revenue exceeding 400 million yuan and setting a 2026 target of at least 540 million yuan in revenue and 100 million yuan in profit, indicating confidence in growth prospects [1] Group 2 - In the recent stock performance, Xinyi Medical's B-share price showed volatility over the past week, with a 5-day change of -0.57%, and the latest stock price at 48.50 HKD. The trading volume during this period was approximately 4.57 million HKD, with technical indicators suggesting short-term adjustment pressure [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 2. 股份分類 | ...